Blog
Article
October marks National Breast Cancer Awareness Month, an opportunity and a call to reflect on the latest research and deepen understanding of this pervasive disease.
October marks National Breast Cancer Awareness Month, an opportunity and a call to reflect on the latest research and deepen understanding of this pervasive disease. Breast cancer is the most commonly diagnosed cancer among women in the US, with approximately 1 in 8 women (13.1%) expected to receive a breast cancer diagnosis, and 1 in 43 (2.3%) expected to die from the disease in 2024. Breast cancer is not limited to women; approximately 2,790 cases will be diagnosed in men, with 530 male fatalities from breast cancer in 2024. These staggering rates highlight the significance of early detection and the need for ongoing research and screening education.
The most common sign of breast cancer is a painless lump in the breast or underarm lymph nodes, often without accompanying symptoms, and is easily treated. Additional signs and symptoms may include breast pain or heaviness, dimpling, swelling, thickening, redness, and nipple changes or discharge. Breast cancer is classified based on several factors, including the stage at diagnosis, microscopic appearance, and molecular features. The staging of breast cancer is particularly important, as it helps determine the extent and spread of disease, informing disease outcome and guiding treatment options.
Mammography screening is essential for early cancer detection. The US Preventative Services Task Force recommends that women who are 40 to 74 years old and are at average risk for breast cancer get a mammogram every 2 years. For many women, mammograms are the best way to find breast cancer early, before a tumor is big enough to feel or cause symptoms. For women at high risk, a breast MRI is used along with mammograms for screenings. Disparities in mammography screening are most prevalent among racial/ethnic minority groups and low-income women. The significant breast cancer mortality rates experienced in both Hispanic and African American populations are found to be connected to delayed screening.
High quality, patient-centered care is essential for improving the overall well-being of breast cancer patients. Addressing side effects is a high priority, as they can significantly impact quality of life. While breast cancer treatment is required and helpful in most cases, each type of treatment can cause both temporary and long-term side effects. Chemotherapy, one of the most common treatments for breast cancer, includes side effects such as hair loss, mouth sores, fatigue, loss of appetite, nausea and vomiting, difficulty with memory and concentrating, and more. It is essential for the health care team to prepare patients about the side effects and provide options to manage them.
Breast cancer supportive therapy includes a wide variety of services to help patients manage issues surrounding a cancer diagnosis, including:
By integrating these services into treatment plans, health care providers can enhance patient experiences and outcomes. When breast cancer patients have symptoms and emotional distress under control, they may be more likely to be able to complete treatments. Encouraging regular screenings and open discussions about risk factors can play a critical role in saving lives. This month serves as a powerful reminder of the ongoing need for encouraging patients to take proactive steps in their breast health and education.
The Association of Cancer Care Centers (ACCC) is dedicated to advancing breast cancer care through its education programming and research. In 2023, ACCC launched a reassessment survey focused on the current landscape of breast cancer gene (BRCA) mutation testing. The survey aimed at assessing the status of barriers and challenges of cancer care teams, seeking to enhance genetic counseling and testing access to improve treatment outcomes and patient engagement.
Breast cancer that is hormone receptor-positive (HR+) with negative human epidermal growth factor receptor (HER2-) is the most common subtype of breast cancer, accounting for 70% of breast cancer cases. The complex treatment regimen (tailored to an individual patient) can include hormone therapy, chemotherapy, or a combination. ACCC has programs to address challenges in oral therapies for HR+, HER2- treatment and patient outcome optimization for those with metastatic HR+, HER2- breast cancer. The complex and evolving treatment landscape for the locally advanced or metastatic version of this cancer requires these programs to identify challenges in these oral therapies and treatment methodologies to provide methods to better support patients.
In addition, ACCC has partnered with the Tigerlily Foundation on an initiative to capture patient and caregiver challenges for triple negative breast cancer in African American women. Using this information on disparities in care, a patient-provider care sequence plan was developed for the entire multidisciplinary cancer care team to eliminate identified knowledge and practice gaps.